SEC Form 4 · accession 0001209191-16-147236

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Oct 26, 2016

Accepted (ET)

Oct 28, 2016 · 1:12 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Oct 26, 2016	M	6,500	$36.30	A	274,725	D
Common Stock^F2,F3	Oct 26, 2016	S	2,000	$77.80	D	272,725	D
Common Stock^F2,F4	Oct 26, 2016	S	1,700	$78.92	D	271,025	D
Common Stock^F2,F5	Oct 26, 2016	S	1,100	$80.06	D	269,925	D
Common Stock^F2,F6	Oct 26, 2016	S	1,600	$80.74	D	268,325	D
Common Stock	Oct 26, 2016	S	100	$81.85	D	268,225	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	78,200	I	Common Stock Held In Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F7	$36.30	Oct 26, 2016	M	6,500	D	—	Jan 23, 2017	Common Stock	6,500	73,000	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $77.80 (range $77.31 to $78.25).
F4Open market sales reported on this line occurred at a weighted average price of $78.92 (range $78.33 to $79.23).
F5Open market sales reported on this line occurred at a weighted average price of $80.06 (range $79.43 to $80.41).
F6Open market sales reported on this line occurred at a weighted average price of $80.74 (range $80.45 to $81.19).
F7Fully vested.